Quince Therapeutics, Inc.: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics (Nasdaq: QNCX) reported Q2 2026 results and a corporate update. It completed the stock-for-stock acquisition of Orphai, adding inhaled rapamycin LAM-001 to its pipeline. Quince closed a $115M private placement, with up to $83M more via warrants. Cash was $116M at June 30, 2026, funding operations through end-2028. Net loss was $75.5M.
How this was made
The 30-second read
Why it matters
The combination of a completed acquisition, a sizable upfront private placement, and explicit Phase 2b/Phase 2 data timing provides a clearer path for valuation modeling and near-to-medium term catalyst planning.
Market read
Traders can reprice QNCX based on the completed deal, financing proceeds, cash runway through end-2028, and the next major clinical readouts.
What to watch
G&A jumped materially due to acquisition-related stock-based comp and professional fees; investors may discount the cash runway if burn accelerates with Phase 2b ramp.
Background
Quince is a clinical-stage biopharma focused on underserved diseases; this update follows its stock-for-stock merger to acquire Orphai and adds LAM-001 to its pipeline.
Ticker impact
Quince completed the Orphai acquisition and closed a $115M private placement, adding LAM-001 and extending cash runway through end-2028.
Likely near-term positive bias on deal financing clarity and pipeline expansion, with volatility around future trial readouts (PH-ILD 1Q28, BOS 1Q27).
The article discloses a completed acquisition, upfront financing size, cash balance ($116M), and specific anticipated clinical timelines, which are actionable for biotech risk/reward positioning.
Market effects
Reinforces investor appetite for late-stage pulmonary pipeline assets and inhaled mTOR-inhibition strategies in PH-related indications.
Limited, primarily US biotech sentiment given South San Francisco-based issuer and Nasdaq listing.
Moderate, as pulmonary hypertension and post-transplant BOS are globally relevant but the disclosure is company-specific.
Counterpoint
The financing and reverse splits highlight ongoing capital needs; clinical timelines (1Q27-1Q28) are long, so near-term fundamentals may still be dilution-driven.
Key entities
- public_companyQuince Therapeutics, Inc.
Nasdaq-listed clinical-stage biopharmaceutical company reporting Q2 2026 results and corporate update.
- public_companyOrphai Therapeutics
Clinical-stage biotech acquired by Quince via stock-for-stock merger, bringing LAM-001 into Quince’s pipeline.
- drug_candidateLAM-001
Once-daily inhaled rapamycin (sirolimus) formulation targeting mTOR pathway for PH-ILD, BOS, and SAPH.
